• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[深静脉血栓形成的治疗。溶栓与肝素]

[The treatment of deep venous thrombosis. Thrombolysis vs heparin].

作者信息

Schmutzler R

出版信息

Phlebologie. 1990 Nov-Dec;43(4):656-65; discussion 666.

PMID:2093922
Abstract

Acute and subacute deep venous thrombosis can be followed by two serious complications: pulmonary embolism feared in the early stadium and the postthrombotic syndrome (PTS) as a late complication. After a lapse of months and years there might appear a complete or incomplete recanalization, but the valves of the veins will be destroyed. Therefore it is understandable to strive first an active therapy as thrombectomy or thrombolysis to remove thrombosis. There will be released a physiological tissue plasminogen activator from the endothelium of the vein increasing a local fibrinolytic activity. But it is not strong enough to reopen the occlusion within a few days. This is only possible adding exogenous activators as streptokinase, urokinase and recently rt-PA. Heparin is well known at low-dose subcutaneously for thrombosis prophylaxis. The high doses of heparin infusion intravenously with 30-40,000 units daily are used "therapeutically" inhibiting growth-promotion of the thrombus and reducing the incidence of pulmonary embolism markedly. In respect of a postthrombotic syndrome (oedema, leg ulcers) it needs the evaluation of the early and follow up late results and the analysis of efficiency and risk of the two models of treatment. It was necessary comparing the success rate of reopening of the occluded veins after some days and follow up 5 or 6 years in clinical studies. The reopening rate in thrombolysis was about 3 times higher than in heparin therapy. But in contrast bleeding was 3 times lower in heparin therapy. For the long term follow up, physical examination, doppler-sonography phlebodynamometry and vein occlusion plethysmography were assessed. The acute intervention, regarding treatment, turned out to be the crucial prognostic parameter. Syndromes and clinical findings did indeed correlate quite well with the outcome of fibrinolytic treatment. Postthrombotic syndrome was rare in cases with complete patency. In cases where patency was only partially or not at all achieved, postthrombotic syndrome was present to a higher degree the more central and the more extensive the remaining thrombus was. In deep venous thrombosis of the lower extremity thrombolytic therapy is recommended mostly to younger patients with acute, the popliteal and the femoral vein including thrombosis, except of contraindications. More over in each of an individual case it has to be decided whether the aggressive or conservative therapy is to prefer.

摘要

急性和亚急性深静脉血栓形成可能会引发两种严重并发症

早期阶段令人担忧的肺栓塞以及作为晚期并发症的血栓形成后综合征(PTS)。数月或数年之后,可能会出现完全或不完全再通,但静脉瓣膜会遭到破坏。因此,首先努力采取诸如血栓切除术或溶栓术等积极治疗措施以清除血栓是可以理解的。静脉内皮会释放一种生理性组织纤溶酶原激活剂,从而增强局部纤维蛋白溶解活性。但它的强度不足以在数天内重新开通闭塞血管。只有添加外源性激活剂,如链激酶、尿激酶以及最近的rt-PA,才有可能实现这一点。肝素以低剂量皮下注射预防血栓形成广为人知。静脉内每日输注30000 - 40000单位的高剂量肝素被用于“治疗”,以抑制血栓的生长并显著降低肺栓塞的发生率。对于血栓形成后综合征(水肿、腿部溃疡),需要评估早期和随访后期结果,并分析两种治疗模式的有效性和风险。在临床研究中,有必要比较数天后闭塞静脉重新开通的成功率,并随访5或6年。溶栓治疗的再通率比肝素治疗高约3倍。但相比之下,肝素治疗的出血发生率低3倍。对于长期随访,评估了体格检查、多普勒超声静脉血流动力学测定和静脉闭塞体积描记法。关于治疗的急性干预结果被证明是关键的预后参数。综合征和临床发现确实与纤维蛋白溶解治疗的结果密切相关。在完全通畅的病例中,血栓形成后综合征很少见。在通畅仅部分实现或根本未实现的病例中,剩余血栓越靠近中心且范围越广,血栓形成后综合征的程度就越高。对于下肢深静脉血栓形成,除有禁忌证外,大多建议对患有急性、腘静脉和股静脉血栓形成的年轻患者进行溶栓治疗。此外,在每个具体病例中,都必须决定是选择积极治疗还是保守治疗。

相似文献

1
[The treatment of deep venous thrombosis. Thrombolysis vs heparin].[深静脉血栓形成的治疗。溶栓与肝素]
Phlebologie. 1990 Nov-Dec;43(4):656-65; discussion 666.
2
Studies on the medical treatment of deep vein thrombosis.深静脉血栓形成的医学治疗研究。
Acta Med Scand Suppl. 1985;704:1-68.
3
[Fibrinolytic therapy in deep venous thrombosis of the upper and lower extremity].[纤维蛋白溶解疗法治疗上肢和下肢深静脉血栓形成]
Fortschr Med. 1977 Apr 7;95(13):858-66.
4
[Deep venous thromboses--established treatment procedures and new trends].[深静脉血栓形成——既定治疗程序与新趋势]
Z Kardiol. 1993;82 Suppl 2:49-59.
5
[Long-term results following fibrinolytic treatment of deep venous thromboses in the area of the pelvis and leg].[盆腔和腿部深静脉血栓形成的纤维蛋白溶解治疗的长期结果]
Vasa. 1989;18(1):48-55.
6
Streptokinase of heparin in the treatment of deep vein thrombosis. Follow-up results of a prospective study.链激酶联合肝素治疗深部静脉血栓形成。一项前瞻性研究的随访结果。
Acta Med Scand. 1982;211(1-2):65-8.
7
A comparative randomized trial of low-dose versus high-dose streptokinase in deep vein thrombosis of the thigh.低剂量与高剂量链激酶治疗大腿深部静脉血栓形成的比较随机试验。
Thromb Haemost. 1984 Apr 30;51(2):261-5.
8
Thrombolytic therapy for deep vein thrombosis.深静脉血栓形成的溶栓治疗。
Am J Surg. 1985 Oct 8;150(4A):50-3.
9
Thrombolytic treatment of portal thrombosis.门静脉血栓形成的溶栓治疗。
Hepatogastroenterology. 2003 Nov-Dec;50(54):2098-100.
10
Cerebral venous congestion as indication for thrombolytic treatment.脑静脉淤血作为溶栓治疗的指征。
Cardiovasc Intervent Radiol. 2007 Jul-Aug;30(4):675-87. doi: 10.1007/s00270-007-9046-1.

引用本文的文献

1
Time-Restricted Salutary Effects of Blood Flow Restoration on Venous Thrombosis and Vein Wall Injury in Mouse and Human Subjects.血流恢复对静脉血栓形成和静脉壁损伤的时间限制有益效应:来自小鼠和人类受试者的研究。
Circulation. 2021 Mar 23;143(12):1224-1238. doi: 10.1161/CIRCULATIONAHA.120.049096. Epub 2021 Jan 15.